Outset Medical, Inc. OM

Company Overview

Outset Medical, Inc. is a U.S.-based medical technology company focused on dialysis systems for patients with kidney disease. The company operates in the healthcare technology and renal care industries and is best known for developing and commercializing the Tablo Hemodialysis System, an integrated dialysis platform designed for use in acute care settings and home dialysis environments. Outset Medical generates revenue primarily through sales of dialysis systems, recurring consumables, service agreements, and related support offerings tied to the installed base of Tablo devices. Its customers include hospitals, health systems, dialysis providers, and patients transitioning to home-based care.

The company was founded in 2003 and later became publicly traded on the Nasdaq under the ticker OM. Outset Medical positioned itself around simplifying dialysis delivery through automation, connectivity, and reduced infrastructure requirements compared with conventional dialysis systems. Public filings and industry reporting indicate that the company’s strategic differentiation centers on portability, ease of use, integrated water purification capabilities, and software-enabled treatment management intended to support decentralized dialysis care models.